Triglyceride-Glucose Index Is an Independent Predictor of Coronary Artery Calcification Progression in Patients With Chronic Kidney Disease
Source : https://www.krcp-ksn.org/journal/view.php?doi=10.23876/j.krcp.23.264
Coronary artery calcification (CAC) is highly prevalent in patients with chronic kidney disease (CKD) and is associated with major adverse cardiovascular events and metabolic disturbances. The triglyceride-glucose index (TyGI), a...
A 1-point increase in the triglyceride-glucose index was related to increased risk of coronary artery calcification progression after adjustment.
Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1
Source : https://pubmed.ncbi.nlm.nih.gov/38710625/
Familial hypobetalipoproteinemia (FHBL) 1 is a rare genetic disorder with an autosomal codominant mode of inheritance and is caused by defects in the apolipoprotein (apo) B (APOB) gene that disable...
Although homozygous or compound heterozygotes of familial type 1 hypobetalipoproteinemia (HoFHBL1) and abetalipoproteinemia cannot be distinguished from the clinical manifestations and laboratory findings of the proband, moderate hypolipidemia in first-degree relatives may help diagnose HoFHBL1.
Metabolic Dysregulation and Its Multifaceted Impact on Cardiovascular Autonomic Control in Type 2 Diabetes Mellitus: Insights From Comprehensive Assessment
Background: Type 2 diabetes mellitus (T2DM) is associated with a spectrum of metabolic dysfunctions that significantly elevate the risk of cardiovascular disorders. Understanding the intricate relationship between metabolic control and...
Glycemic variability and dyslipidemia (elevated TG/LDL cholesterol, reduced HDL cholesterol) were associated with CV autonomic dysfunction.
Zerlasiran was well tolerated and produced sustained reductions in lipoprotein(a) concentrations.
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Source : https://pubmed.ncbi.nlm.nih.gov/38587249/
In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis...
Each dose of olezarsen also significantly reduced the levels of APOC3, apolipoprotein B, and non-HDL cholesterol, with no significant change in the LDL cholesterol level.